it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done.
.-related side effects. its manufacturer, eli lilly, plans to submit a new drug application to the fda in the second half of 2018.
.
.
. is the place to come for breaking news, analysis and for stories that are just too interesting � or too entertaining � to pass up.
.